1. Home
  2. MESO vs AHCO Comparison

MESO vs AHCO Comparison

Compare MESO & AHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • AHCO
  • Stock Information
  • Founded
  • MESO 2004
  • AHCO 2012
  • Country
  • MESO Australia
  • AHCO United States
  • Employees
  • MESO N/A
  • AHCO N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • AHCO Medical/Nursing Services
  • Sector
  • MESO Health Care
  • AHCO Health Care
  • Exchange
  • MESO Nasdaq
  • AHCO Nasdaq
  • Market Cap
  • MESO 1.3B
  • AHCO 1.2B
  • IPO Year
  • MESO N/A
  • AHCO N/A
  • Fundamental
  • Price
  • MESO $15.81
  • AHCO $9.61
  • Analyst Decision
  • MESO Buy
  • AHCO Strong Buy
  • Analyst Count
  • MESO 4
  • AHCO 5
  • Target Price
  • MESO $18.00
  • AHCO $13.40
  • AVG Volume (30 Days)
  • MESO 148.6K
  • AHCO 1.2M
  • Earning Date
  • MESO 09-02-2025
  • AHCO 08-05-2025
  • Dividend Yield
  • MESO N/A
  • AHCO N/A
  • EPS Growth
  • MESO N/A
  • AHCO N/A
  • EPS
  • MESO N/A
  • AHCO 0.54
  • Revenue
  • MESO $5,670,000.00
  • AHCO $3,240,757,000.00
  • Revenue This Year
  • MESO $177.23
  • AHCO $1.41
  • Revenue Next Year
  • MESO $314.04
  • AHCO $4.26
  • P/E Ratio
  • MESO N/A
  • AHCO $17.91
  • Revenue Growth
  • MESO N/A
  • AHCO N/A
  • 52 Week Low
  • MESO $6.00
  • AHCO $7.11
  • 52 Week High
  • MESO $22.00
  • AHCO $11.70
  • Technical
  • Relative Strength Index (RSI)
  • MESO 58.97
  • AHCO 54.59
  • Support Level
  • MESO $14.68
  • AHCO $9.22
  • Resistance Level
  • MESO $16.38
  • AHCO $9.64
  • Average True Range (ATR)
  • MESO 0.44
  • AHCO 0.43
  • MACD
  • MESO -0.14
  • AHCO -0.01
  • Stochastic Oscillator
  • MESO 67.05
  • AHCO 43.70

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.

Share on Social Networks: